Clinical Guidelines

Current major society recommendations, summarized for bedside use. Each page lists the key changes from the prior edition, clinical takeaways, quick-reference tables, and the trials that shaped the guidance.

Cardiology

2 guidelines
American Heart Association / American College of Cardiology / Heart Failure Society of America

2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure (with Post-Guideline Evidence Landscape Through 2025)

Core US guideline for HF management: four-pillar GDMT for HFrEF, SGLT2 inhibitors across the EF spectrum, and risk-based advanced therapy referral. Read together with post-guideline trials (FINEARTS-HF, STEP-HFpEF, IRONMAN) that have since expanded the evidence base for HFpEF/HFmrEF.

7 key changes
American Heart Association / American College of Cardiology (13-organization multisociety)

2025 AHA/ACC Multisociety Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults

Reaffirms the 130/80 mm Hg threshold, adopts the PREVENT risk calculator in place of the pooled cohort equations, and strengthens recommendations on resistant hypertension, primary aldosteronism screening, pregnancy, and renal denervation.

8 key changes

Critical Care

1 guideline
Society of Critical Care Medicine (SCCM) and European Society of Intensive Care Medicine (ESICM)

Surviving Sepsis Campaign 2026 International Guidelines for Management of Sepsis and Septic Shock in Adults

Refines the 1-hour bundle into a phenotype-aware approach, de-emphasizes fixed 30 mL/kg fluid resuscitation, and strengthens antibiotic stewardship within sepsis care.

7 key changes

Dermatology

1 guideline
American Academy of Dermatology / National Psoriasis Foundation

AAD-NPF 2019 Joint Guidelines of Care for the Management and Treatment of Psoriasis with Biologics (with Post-Guideline Evidence)

Current AAD-NPF joint guideline on biologic therapy for plaque psoriasis. Read together with post-guideline head-to-head trials (IMMerge, ECLIPSE) and the 2022 FDA approval of oral deucravacitinib (TYK2) informing current biologic class positioning.

7 key changes

Endocrinology

1 guideline
American Diabetes Association

ADA Standards of Care in Diabetes — 2026

Organ-protection-first approach to type 2 diabetes: choose therapy by cardiorenal profile, not by A1c alone, and integrate CGM and tirzepatide across the care spectrum.

8 key changes

Hepatology

1 guideline
American Association for the Study of Liver Diseases

AASLD 2023 Practice Guidance on the Clinical Assessment and Management of MASLD (with November 2025 Semaglutide Update)

Adopts the MASLD/MASH nomenclature, formalizes a non-invasive staging pathway anchored on FIB-4 and elastography, and — via the November 2025 AASLD practice update — adds semaglutide as a recommended pharmacotherapy for adults with MASH and F2–F3 fibrosis.

7 key changes

Infectious Diseases

1 guideline
Centers for Disease Control and Prevention (MMWR)

CDC 2025 Clinical Recommendation for Injectable Lenacapavir as HIV Pre-Exposure Prophylaxis (with 2024 CDC Doxy-PEP Guidelines)

CDC strongly recommends twice-yearly injectable lenacapavir as an HIV PrEP option alongside existing oral and injectable regimens. Read together with CDC's 2024 doxycycline post-exposure prophylaxis recommendation for bacterial STI prevention in MSM and transgender women.

7 key changes

Nephrology

1 guideline
Kidney Disease: Improving Global Outcomes (KDIGO)

KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease

Consolidates CKD staging, risk stratification, and disease-modifying therapy into a single framework, with expanded guidance on SGLT2 inhibitors, finerenone, and GLP-1 receptor agonists across eGFR ranges.

8 key changes

Neurology

1 guideline
American Academy of Neurology

AAN Practice Guideline: Disease-Modifying Therapies for Adults with Multiple Sclerosis (2018, Reaffirmed 2024) with Post-Guideline Evidence

Current AAN practice guideline on starting, switching, and stopping MS disease-modifying therapy (reaffirmed October 2024). Read together with post-guideline evidence — including HERCULES (tolebrutinib for non-relapsing SPMS, 2025) and DISCOMS (DMT discontinuation in older stable patients, 2023) — that informs shared decision-making.

7 key changes

Pulmonology

1 guideline
Global Initiative for Chronic Obstructive Lung Disease

GOLD 2026 Global Strategy for Prevention, Diagnosis and Management of COPD

Sixth major revision of the GOLD strategy document; emphasizes earlier and better COPD detection, completely revises the exacerbations and multimorbidity chapters, and adds a new chapter on AI and emerging technologies in COPD.

8 key changes